TGTX- JP Morgan Presentation 1.13.26v2.pdf

《TGTX- JP Morgan Presentation 1.13.26v2.pdf》由会员分享，可在线阅读，更多相关《TGTX- JP Morgan Presentation 1.13.26v2.pdf（20页珍藏版）》请在三个皮匠报告上搜索。

1、TAKING ON MSTG Therapeutics(NASDAQ:TGTX)Presenter:Michael S.Weiss,Chairman&CEO January 2026J.P.Morgan Healthcare Conference Forward Looking Safe Harbor Statement2This presentation contains forward-looking statements that involve a number of risks and uncertainties.For those statements,we claim the p

2、rotection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.Such forward looking statements include but are not limited to statements regarding the estimated preliminary financial results referred to above,expectations for the timing

3、and success of the commercialization and availability of BRIUMVI(ublituximab-xiiy)for relapsing forms of multiple sclerosis(RMS)in the United States,or any jurisdictions outside of the United States;anticipated healthcare professional(HCP)and patient acceptance and use of BRIUMVI for the approved in

4、dications;expectations of future revenue for BRIUMVI,or our expenses or profit estimates or targets;our ability to execute the proposed share repurchase program;expectations and timing for our clinical trials of subcutaneous ublituximab(the active ingredient in BRIUMVI),and sometimes referred to as

5、subcutaneous BRIUMVI,including feasibility,approvability and commercial acceptance;expectations and timing for our ENHANCE Phase 3 trial combining day 1 and day 15 doses,including,feasibility,approvability and commercial acceptance and impact on BRIUMVI sales;and expectations and timing for any of o

6、ur pipeline products or programs,including Azer-cel or BRIUMVI in MG.Additional factors that could cause our actual results to differ materially include the following:the Companys ability to continue to commercialize BRIUMVI;the risk that trends in prescriptions are not maintained or that prescripti